ACT-246475 is a selective and reversible P2Y 12 receptor antagonist inducing inhibition of platelet aggregation (IPA). A randomized, double-blind, placebo-controlled, parallel-design study was performed to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating single subcutaneous doses of ACT-246475 (1, 2, 4, 8, 16, or 32 mg) in healthy male subjects (N = 8 per dose, 3:1 active:placebo ratio). Pharmacodynamic effects were assessed based on maximum platelet aggregation and P2Y 12 reaction units using light transmission aggregometry and VerifyNow R assays, respectively. ACT-246475 was safe and well tolerated up to 32 mg based on adverse event data and absence of clinically relevant changes in hematology, biochemistry, vital signs, and electrocardiogram variables. Median time to reach maximum plasma concentration was 0.5-0.75 hours, and geometric mean terminal half-life ranged from 1.3 to 9.2 hours across the tested dose range. Exposure to ACT-246475 was dose proportional across all dose groups. The maximal %IPA was reached within 30 minutes after subcutaneous administration of ACT-246475. A dose-dependent duration and extent of effect were observed based on area under the effect curve and maximum effect data. Similar results were observed for maximum platelet aggregation and P2Y 12 reaction units. The %IPA was ࣙ85% at doses ࣙ2 mg. This level of %IPA was extended to at least 12 hours in the 32-mg dose group. The safety and pharmacokinetic/pharmacokinetic profile with quick onset and adequate duration of IPA support further investigation in patients with coronary artery disease.
The first-line therapy for treatment of acute coronary syndromes includes acetylsalicylic acid (Aspirin R ) in combination with a selective P2Y 12 receptor antagonist to trigger inhibition of platelet aggregation (IPA). 1 Platelets can be activated by multiple factors such as ADP. 2 Following thrombosis, ADP, which is released at the site of vascular damage and atherosclerotic plaque disruption, 3 can bind G protein-coupled purinergic P2Y 1 and P2Y 12 receptors that are found mainly on the surface of platelets. 4 The P2Y 1 receptor triggers rapid and transient aggregation, whereas signaling from the P2Y 12 receptor causes sustained and irreversible aggregation leading to thrombus growth in pathological conditions. 5 Two main classes of P2Y 12 receptor antagonists are currently approved for the treatment of acute coronary syndromes. Thienopyridines (ie, clopidogrel and prasugrel) are inactive oral prodrugs requiring metabolic conversion to irreversibly bind and inactivate the P2Y 12 receptor. 6 In contrast, ticagrelor (for oral use) and cangrelor (for intravenous use) are nonthienopyridine receptor antagonists that reversibly bind the P2Y 12 receptor with a quicker onset of action compared to thienopyridine compounds. 7, 8 In the landscape of P2Y 12 receptor antagonists, the need for an early intervention has been highlighted by the guidelines of the European Society of Cardiology 9 and the American College of Cardiology/American Heart Association, 10 which identified the prehospital phase as the most critical in reducing mortality and reiterated that efforts must be made to reduce the delay for treatment initiation.
ACT-246475 is a potent, reversible, and selective nonthienopyridine antagonist of the P2Y 12 receptor that is being developed for subcutaneous (SC) selfadministration using an injector for the early treatment intervention of a suspected acute myocardial infarction. 11 Preclinical studies using the ferric chloride model in rats showed that ACT-246475 displays a wider therapeutic window with respect to bleeding risk than clopidogrel 12 and ticagrelor. 13 In the first-inhuman study, oral administration of the prodrug (ACT-281959) and the active moiety ACT-246475 was well tolerated, characterized by rapid absorption and elimination, but produced low exposure to ACT-246475 and hence limited pharmacodynamic (PD) effects. 11 A SC formulation of the active moiety ACT-246475 has recently been developed.
In this study (NCT03173625), single ascending doses of ACT-246475 were investigated in healthy male subjects.
Methods

Subjects
Written informed consent was obtained from each individual participating in the study. The protocol and informed consent documentation were approved by the IntegReview IRB (Austin, Texas). The study was performed at Biotrial (Newark, New Jersey) according to good clinical practice and in accordance with the principles of the Declaration of Helsinki.
Healthy male subjects aged between 19 and 45 years with a body mass index between 18.0 and 31.0 kg/m 2 were included. Screening assessments included medical history, medications taken during the 3 months preceding the screening visit, physical examination, measurement of body weight and height, clinical laboratory tests, recording of vital signs, and standard electrocardiogram (ECG). Main exclusion criteria included history of orthostatic hypotension, maximum platelet aggregation <40% on 20 μmol/L ADP activation, and known platelet disorders or history of bleeding disorders. Previous treatment with acetylsalicylate, nonsteroidal anti-inflammatory drugs, or any medication with blood-thinning activity within 2 weeks before administration of the study drug was not permitted.
Study Design
This single-center, randomized, double-blind, placebocontrolled study had a parallel-group design. A total of 48 male subjects were enrolled, and 8 subjects were assigned per dose group (ratio 3:1 for active:placebo). ACT-246475 or placebo was administered as a single SC injection in the morning of day 1, under fasted conditions.
The safety margins calculated for the starting dose of 1 mg were 560 and 280 based on area under the plasma concentration-time curve from 0 to infinity (AUC 0-Ý ) and maximum plasma concentration (C max ) data, respectively, with reference to the no-observed-adverseeffect levels in rats in 4-week toxicity studies. Although not fully elucidated in humans, the metabolism of ACT-246475 evaluated in vitro and in vivo revealed that ACT-246475 is neither a substrate of cytochrome P450 enzymes nor an inhibitor or inducer of cytochrome P450 enzymes (Idorsia data on file).
ACT-246475 was administered as single SC doses of 1, 2, 4, 8, 16, or 32 mg. The lyophilized powder was reconstituted using water for injection to obtain stock solutions at a concentration of 20 mg/mL. For the doses of 1, 2, 4, and 8 mg, further dilutions with sterile saline (0.9 % w/v sodium chloride) were performed to prepare solutions of 2, 4, 8, and 16 mg/mL, respectively. The volume of ACT-246475 injected in the thigh was between 0.5 mL (for doses from 1 to 8 mg) and 0.8 mL (dose of 16 mg). For the dose of 32 mg, 2 simultaneous injections of 0.8 mL, 1 in each thigh, were performed. Sterile saline (0.9 % w/v sodium chloride) was used as placebo treatment. All injections were performed by the investigator.
After each dose group, there was a review of blinded safety, pharmacokinetic (PK), and PD data for dose escalation decisions.
Pharmacokinetic Assessments
Blood samples of about 4 mL were collected in EDTA tubes predose and at 5, 10, 15, 20, 25, and 30 minutes and 1, 1.5, 2, 3, 4, 5, 6, 8, 12, 24, 36, and 48 hours postdose. After centrifugation, plasma was transferred into a polypropylene tube and stored at below -70°C (±5°C) pending analysis.
Plasma concentrations of ACT-246475 were determined using a validated liquid chromatography coupled to tandem mass spectrometry assay with a lower limit of quantification of 1 ng/mL. 11 The method was linear in the concentration range 1-2000 ng/mL. Analysis of quality-control samples of all runs showed that interbatch coefficients of variation (precision) were <5.9%, whereas the average intrabatch accuracy was in the range of 96.0% to 102.7%.
Noncompartmental PK analyses were performed using Professional WinNonlin 6.4 software (Pharsight Corp, Mountain View, California). The variables C max and time to reach C max were directly obtained from the plasma concentration-time profiles, AUC from 0 to the last measured concentration above the limit of quantification (AUC 0-t ) was calculated using the trapezoidal method, 14 and terminal half-life was calculated as ln 2/λz, where λz is the terminal elimination rate constant estimated by log-linear regression analysis. Total body clearance was calculated as dose/AUC 0-Ý .
Dose proportionality was assessed across the dose range for C max and AUC using the power model. 15 C max and AUC were assumed to be log-normally distributed. 16 Dose proportionality was established if the 90%CI of the slope was completely contained in the Pharmacodynamic Assessments ADP-induced platelet aggregation was measured ex vivo during 24 hours postdose. Two methods were applied: light transmission aggregometry (LTA, reference gold standard) and VerifyNow R (novel point-ofcare). 17 Blood samples of 13 mL were collected: the first 2 mL of blood was discarded, and, thereafter, blood was drawn into 2 open 3.5-mL (for LTA) and 1 open 2-mL (for VerifyNow R ) Phe-Pro-Argcholormethylketone collection tubes. Blood samples were maintained at room temperature.
Sample Preparation for LTA and VerifyNow R Measurements Blood for LTA measurements was sampled predose and at 15 and 30 minutes and 3, 4, 5, 12, and 48 hours postdose and was subsequently centrifuged with brakes switched off at 200g for 7 minutes at 20°C to obtain platelet-rich plasma (PRP), which was transferred into a crystal plastic tube. The remaining blood was again centrifuged at 1800g for 10 minutes at room temperature, with activated slow braking. The platelet-poor plasma was transferred into another crystal plastic tube. Platelet count was measured using a cell counter, and PRP was adjusted to a final platelet count of 
Pharmacodynamic Analysis
The percentage change of aggregation from baseline %IPA(MPA) and PRU (%IPA[PRU]) was derived from MPA and PRU values (using LTA and VerifyNow R assays), respectively, and calculated per subject and time point according to the formula:
where %IPA(X) t represents %IPA derived from the PD variable (MPA or PRU) at time t postdose (%IPA [MPA] and %IPA[PRU], respectively). X 0 and X t are PD measurements at baseline and time t postdose, respectively. Maximum effect (E max ) was defined as the maximum %IPA(MPA) (E max,MPA ) or %IPA(PRU) (E max,PRU ) based on LTA or VerifyNow R assays, respectively. The area under the effect %IPA curve (AUEC) from 0 to 48 hours postdose was calculated based on %IPA(PRU) because more time points were used for measuring PRU than for MPA.
One-way ANOVAs followed by Tukey multiplecomparisons tests were used to perform intergroup (ie, each dose group vs pooled placebo group) timematched comparisons. Differences were considered to be statistically significant at P < .05.
PK/PD Relationships
The %IPA(MPA) and %IPA(PRU) were plotted against log concentration of ACT-246475. The best-fit concentration causing 50% inhibition (IC 50 ) was computed using GraphPad Prism 7 (La Jolla, California).
Safety and Tolerability Evaluations
Safety and tolerability were evaluated by monitoring adverse events (AEs), vital signs measurements (supine blood pressure), 12-lead ECG recordings, clinical laboratory, physical, and neurological examinations at screening, predose, and up to 72 hours postdose.
Results
Subjects
A total of 48 subjects participated in the study and completed the study according to the protocol. Of those, 24 were black, others were Hispanic or Latino (n = 16), white (n = 4), Asian (n = 1), black/Asian (n = 1), Native American (n = 1), and Haitian (n = 1). The overall mean (SD) age and body mass index were 31.7 (7.1) years and 25.9 (3.2) kg/m 2 , respectively. The dose groups were well balanced with regard to demographic and baseline characteristics.
Safety and Tolerability ACT-246475 was safe and well tolerated up to and including 32 mg based on the AE profile and absence of clinically relevant effects of treatment on the clinical laboratory parameters, ECG recordings, physical examination, and vital sign values observed.
In total, 6 of 48 subjects showed at least 1 AE in the 2-mg (n = 2), 8-mg (n = 3), and placebo groups (n = 1). The most common AEs were headache (n = 2/1 active/placebo) and dizziness (n = 2/0). There were no injection-site reactions, swelling, or pain reported in this study.
All AEs were of mild intensity except for a moderate AE of catheter site erythema and headache in the placebo group (Table 1) . There were no serious AEs or AEs leading to premature study discontinuation. Table 2 ACT-246475 was quickly absorbed with a median t max between 0.50 and 0.75 hour. The geometric mean (95%CI) half-life ranged from 1.3 (1.1-1.6) to 9.2 (6.2-13.8) hours.
Pharmacokinetics
As described in
Pharmacodynamics
Following administration of ACT-246475, extent and duration of IPA were dose dependent. In placebotreated subjects, MPA and PRU data remained essentially unchanged during the study (Figure 2A and 2B) . The baseline of MPA, PRU, and P2Y 12 inhibition data was comparable across all dose groups.
LTA Assay
Mean minimal MPA was 24.7%, 15.7%, 14.8%, 7.6%, 5.2%, and 4.1% after single SC doses of 1, 2, 4, 8, 16, and 32 mg ACT-246475, respectively. As depicted in Figure 2 , the duration of effect increased with the dose. Within 24 to 48 hours after dosing, these effects returned to baseline in all dose groups.
In placebo-treated subjects (N = 12), the mean (SD) E max,MPA was 13.02% (31.04%) with a time to E max of 30 minutes, whereas in the active groups, it dosedependently ranged from 64.38% (12.79%) to 95.54% (2.68%) ( Figure 3A ). E max,MPA (P < .001) was significantly greater following administration of ACT-246475 compared to placebo, and there were no significant differences in E max within active groups.
Mean E max,MPA reached 85% at doses ࣙ4 mg. The duration of the PD effect increased with dose as indicated in Figure 3A . After 48 hours, all %IPA(MPA) measurements were <30%.
VerifyNow
R Assay Mean minimal PRU was 65.6, 8.2, 5.0, 3.7, 2.5, and 2.2 after single SC doses of 1, 2, 4, 8, 16, and 32 mg ACT-246475, respectively. The peak %P2Y 12 inhibition was >85% at doses ࣙ2 mg.
In placebo-treated subjects, the mean (SD) E max,PRU was 15.03% (35.58%), whereas in the active treatment groups it dose-dependently ranged from 71.52% (18.19%) to 99.02% (0.23%). A significantly higher E max,PRU was measured in the active groups (P < .001) compared to placebo. The %IPA(PRU) was <50% after 8, 12, and 24 hours after 8, 16, and 32 mg of ACT-246475, respectively. As depicted in Figure 3B , the duration of the PD effect increased with dose. A, B) represents 90% inhibition. C, The area under the effect curve (AUEC) from 0 to 48 hours after dosing calculated using PRU values. Statistical difference was assessed between treatments using 1-way ANOVA followed by a Tukey multiple-comparisons post hoc test. *P < .05, ***P < .001, ACT-246475 vs placebo. AUEC indicates area under the effect curve; IPA, inhibition of platelet aggregation; MPA, maximum platelet aggregation; PRU, P2Y 12 reaction units.
The mean (SD) AUEC in the placebo group was 514 hour% (332 hour%). Because AUEC was calculated based on %IPA(PRU), a significantly higher AUEC reflecting IPA was observed in active groups (P < .001). Mean (SD) AUEC did not differ to a large extent ( Figure 3C) 
Discussion
In this study ACT-246475 was determined to be safe and well tolerated in healthy male subjects up to the highest tested dose of 32 mg. The AE incidence was low and independent of dose, and there were no clinically relevant changes of ECG, vital signs, or laboratory data. Preclinical studies have previously suggested a wider therapeutic window of ACT-246475 with respect to bleeding risk compared to ticagrelor. 13 This hypothesis is in line with the absence of bleeding events in this study, and it will be interesting to evaluate this finding further in future patient studies.
ACT-246475 was characterized by doseproportional PK, rapid absorption, and elimination. Its half-life increased with dose and ranged from 1.3 to 9.2 hours across the tested dose range. This is presumably related to the inability to reliably estimate the terminal elimination phase in the low-dose groups due to limitations in bioanalytical assay sensitivity precluding the quantification of ACT-246475 at the last sampling time points.
In line with its rapid absorption, ACT-246475 also showed a rapid onset of action indicated by an E max of IPA being reached after approximately 30 minutes. This time to E max was essentially independent of dose ( Figure 3 ) and is shorter than that for orally administered P2Y12 receptor antagonists such as clopidogrel (2-5 hours), prasugrel (1 hour), or ticagrelor (2 hours). 5 Cangrelor also has a quick onset time but can only be administered as an intravenous bolus followed by continuous infusion. 18 The extent and duration of IPA mediated by ACT-246475 appeared to be dose-dependent based on AUEC data (Figure 3 ) and the IPA over time profile ( Figure 2C ). In the treatment of acute myocardial infarction, it will be important to select a dose that warrants a relevant degree of IPA sufficient to support the conduct of percutaneous coronary intervention that should be commenced as soon as possible after an acute myocardial infarction event. Here, single SC doses of ࣙ8 mg ACT-246475 fulfill these requirements, as indicated by >85% IPA for at least 3 hours postdosing. Hence, the extent of IPA is greater compared to that elicited by the thienopyridines clopidogrel or prasugrel, reaching peak IPA of up to approximately 50% and 80%, respectively. 19 Although the IPA is commonly used as primary PD biomarker, it does not necessarily translate into efficacy in reducing mortality because the time to reach a relevant degree of IPA is critical. 9, 10 The time frame for resolution of PD effects also appears suitable for safe transition to subsequent treatment with oral P2Y 12 receptor antagonists. Here, the short duration of action at therapeutic doses may be an advantage. Currently, cangrelor has the shortest offset of action among the approved P2Y 12 receptor antagonists, but it can only be administered intravenously.
In this study, both LTA and VerifyNow R assays were used. The former has been used for many years and is still considered the gold standard for determining the degree of IPA. Currently, the point-of-care VerifyNow R assay is increasingly being used both in the context of clinical studies and in clinical practice. 17, 20 Here, the IPA data generated are consistent when the 2 assays are compared ( Figure 2C ).
In conclusion, based on its safety and tolerability, PK, and PD data, ACT-246475 seems to be a promising, novel P2Y 12 receptor antagonist for early intervention in the context of acute coronary syndrome treatment. It displays some advantages over oral P2Y 12 receptor antagonists (ie, no need for conversion into an active metabolite, short onset/offset of action, almost full inhibition of the P2Y 12 pathway), and, given the single SC administration, it is also easier to use than cangrelor, which requires continuous infusion. Taken together, the data gathered in this study warrant further clinical development in patients with coronary artery disease.
